Concepts (66)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromatography, High Pressure Liquid | 4 | 2013 | 406 | 0.600 |
Why?
|
| Droperidol | 1 | 2010 | 3 | 0.390 |
Why?
|
| Bromocriptine | 1 | 2010 | 7 | 0.390 |
Why?
|
| Haloperidol | 1 | 2010 | 27 | 0.380 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2013 | 173 | 0.290 |
Why?
|
| Ibuprofen | 2 | 2023 | 33 | 0.290 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 63 | 0.220 |
Why?
|
| Skin | 1 | 2023 | 173 | 0.210 |
Why?
|
| Research Design | 1 | 2023 | 292 | 0.200 |
Why?
|
| Drug Stability | 4 | 2016 | 110 | 0.180 |
Why?
|
| Rats | 5 | 2023 | 3261 | 0.160 |
Why?
|
| Noscapine | 1 | 2016 | 11 | 0.140 |
Why?
|
| Reference Standards | 2 | 2012 | 52 | 0.120 |
Why?
|
| Adenosine | 1 | 2013 | 54 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2012 | 5 | 0.110 |
Why?
|
| Glucuronides | 1 | 2012 | 10 | 0.110 |
Why?
|
| Camptothecin | 1 | 2012 | 20 | 0.110 |
Why?
|
| Ticlopidine | 1 | 2011 | 15 | 0.100 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 46 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 65 | 0.100 |
Why?
|
| Animals | 7 | 2023 | 14307 | 0.100 |
Why?
|
| Indoles | 1 | 2012 | 154 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 107 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2010 | 137 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2012 | 1534 | 0.090 |
Why?
|
| Molecular Structure | 1 | 2010 | 467 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 756 | 0.080 |
Why?
|
| Biological Availability | 2 | 2016 | 84 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2016 | 212 | 0.060 |
Why?
|
| Tablets | 1 | 2023 | 8 | 0.060 |
Why?
|
| Technology, Pharmaceutical | 1 | 2023 | 25 | 0.060 |
Why?
|
| Needles | 1 | 2023 | 8 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2023 | 38 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2023 | 57 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 74 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2023 | 182 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 555 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 901 | 0.040 |
Why?
|
| Emulsions | 1 | 2016 | 31 | 0.040 |
Why?
|
| Mannose | 1 | 2016 | 25 | 0.040 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 65 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 171 | 0.030 |
Why?
|
| Cisplatin | 1 | 2016 | 70 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 131 | 0.030 |
Why?
|
| Humans | 5 | 2023 | 34853 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 242 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2016 | 121 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 209 | 0.030 |
Why?
|
| Mice | 2 | 2016 | 5668 | 0.030 |
Why?
|
| Tubercidin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 42 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 818 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 58 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 48 | 0.030 |
Why?
|
| Permeability | 1 | 2012 | 67 | 0.030 |
Why?
|
| Calibration | 1 | 2012 | 55 | 0.030 |
Why?
|
| Solubility | 1 | 2012 | 115 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 294 | 0.030 |
Why?
|
| Swine | 1 | 2012 | 182 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 1681 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1300 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 528 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2128 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 447 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 642 | 0.020 |
Why?
|
| Male | 1 | 2012 | 18870 | 0.010 |
Why?
|